Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
March 09 2023 - 7:00AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced that Chen Schor, President
and Chief Executive Officer, and Nick Harvey, Chief Financial
Officer, will participate in the 2023 Jefferies Biotech on the Bay
Summit being held March 16-17, 2023.
The Adicet Bio team will be available for one-on-one meetings
throughout the conference. Please contact your sales representative
at Jefferies to register for a meeting with the company.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230309005135/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2023 to Jul 2024